AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Statistics
Share Statistics
AbCellera Biologics has 297.99M shares outstanding. The number of shares has increased by 0.88% in one year.
| Shares Outstanding | 297.99M |
| Shares Change (YoY) | 0.88% |
| Shares Change (QoQ) | 0.24% |
| Owned by Institutions (%) | 38.62% |
| Shares Floating | 223.58M |
| Failed to Deliver (FTD) Shares | 6K |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 17.26M, so 5.84% of the outstanding shares have been sold short.
| Short Interest | 17.26M |
| Short % of Shares Out | 5.84% |
| Short % of Float | 7.78% |
| Short Ratio (days to cover) | 5.37 |
Valuation Ratios
The PE ratio is -5.3 and the forward PE ratio is -4.89. AbCellera Biologics's PEG ratio is -0.68.
| PE Ratio | -5.3 |
| Forward PE | -4.89 |
| PS Ratio | 29.91 |
| Forward PS | 9.4 |
| PB Ratio | 0.82 |
| P/FCF Ratio | -4.61 |
| PEG Ratio | -0.68 |
Enterprise Valuation
AbCellera Biologics Inc. has an Enterprise Value (EV) of 1.73B.
| EV / Earnings | -10.61 |
| EV / Sales | 59.95 |
| EV / EBITDA | -8.47 |
| EV / EBIT | -5.49 |
| EV / FCF | -9.25 |
Financial Position
The company has a current ratio of 9.81, with a Debt / Equity ratio of 0.06.
| Current Ratio | 9.81 |
| Quick Ratio | 9.81 |
| Debt / Equity | 0.06 |
| Total Debt / Capitalization | 5.44 |
| Cash Flow / Debt | -1.79 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.15% and return on capital (ROIC) is -22.9%.
| Return on Equity (ROE) | -0.15% |
| Return on Assets (ROA) | -0.12% |
| Return on Capital (ROIC) | -22.9% |
| Revenue Per Employee | $48,377.52 |
| Profits Per Employee | $-273,250 |
| Employee Count | 596 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -37.54M |
| Effective Tax Rate | 0.19 |
Stock Price Statistics
The stock price has increased by -49.01% in the last 52 weeks. The beta is 0.45, so AbCellera Biologics's price volatility has been higher than the market average.
| Beta | 0.45 |
| 52-Week Price Change | -49.01% |
| 50-Day Moving Average | 2.85 |
| 200-Day Moving Average | 2.82 |
| Relative Strength Index (RSI) | 39.31 |
| Average Volume (20 Days) | 4.09M |
Income Statement
In the last 12 months, AbCellera Biologics had revenue of 28.83M and earned -162.86M in profits. Earnings per share was -0.55.
| Revenue | 28.83M |
| Gross Profit | 28.83M |
| Operating Income | -314.77M |
| Net Income | -162.86M |
| EBITDA | -204.15M |
| EBIT | -314.77M |
| Earnings Per Share (EPS) | -0.55 |
Balance Sheet
The company has 156.32M in cash and 60.74M in debt, giving a net cash position of 95.58M.
| Cash & Cash Equivalents | 156.32M |
| Total Debt | 60.74M |
| Net Cash | 95.58M |
| Retained Earnings | 0 |
| Total Assets | 1.36B |
| Working Capital | 674.76M |
Cash Flow
In the last 12 months, operating cash flow was -108.56M and capital expenditures -78.4M, giving a free cash flow of -186.95M.
| Operating Cash Flow | -108.56M |
| Capital Expenditures | -78.4M |
| Free Cash Flow | -186.95M |
| FCF Per Share | -0.64 |
Margins
Gross margin is 100%, with operating and profit margins of -1.09K% and -564.83%.
| Gross Margin | 100% |
| Operating Margin | -1.09K% |
| Pretax Margin | -695.02% |
| Profit Margin | -564.83% |
| EBITDA Margin | -708.04% |
| EBIT Margin | -1.09K% |
| FCF Margin | -648.4% |
Dividends & Yields
ABCL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -23.81% |
| FCF Yield | -27.16% |
Analyst Forecast
The average price target for ABCL is $7, which is 203% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 203% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 1.25 |
| Piotroski F-Score | 3 |